Two-drug combination improves survival for operable pancreatic cancer
The results of a large pan-European study by the European Study Group for Pancreatic Cancer (ESPAC) involving 732 patients has shown that the combination of gemcitabine plus capecitabine adjuvant therapy (following successful resection of the tumour) significantly improved survival. Presented at the American Society for Clinical Oncology1 in Chicago this week, the lead researchers from ...Read More »Two-drug combination improves survival for operable pancreatic cancer